ALBIO Stock Overview
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€16.68|
|52 Week High||€28.78|
|52 Week Low||€13.28|
|1 Month Change||-14.46%|
|3 Month Change||-5.71%|
|1 Year Change||-34.59%|
|3 Year Change||506.55%|
|5 Year Change||299.04%|
|Change since IPO||-7.07%|
Recent News & Updates
|ALBIO||FR Medical Equipment||FR Market|
Return vs Industry: ALBIO underperformed the French Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: ALBIO underperformed the French Market which returned -5.4% over the past year.
|ALBIO Average Weekly Movement||7.5%|
|Medical Equipment Industry Average Movement||7.1%|
|Market Average Movement||6.1%|
|10% most volatile stocks in FR Market||10.5%|
|10% least volatile stocks in FR Market||3.6%|
Stable Share Price: ALBIO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ALBIO's weekly volatility (8%) has been stable over the past year.
About the Company
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products.
Biosynex Fundamentals Summary
|ALBIO fundamental statistics|
Is ALBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALBIO income statement (TTM)|
|Cost of Revenue||€176.12m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||10.08|
|Net Profit Margin||27.19%|
How did ALBIO perform over the long term?See historical performance and comparison
12.0%Current Dividend Yield
Is Biosynex undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALBIO (€16.68) is trading below our estimate of fair value (€252.76)
Significantly Below Fair Value: ALBIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALBIO is good value based on its PE Ratio (1.7x) compared to the French Medical Equipment industry average (13.6x).
PE vs Market: ALBIO is good value based on its PE Ratio (1.7x) compared to the French market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALBIO is good value based on its PB Ratio (1x) compared to the FR Medical Equipment industry average (2.2x).
How is Biosynex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosynex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Biosynex performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALBIO has a high level of non-cash earnings.
Growing Profit Margin: ALBIO's current net profit margins (27.2%) are higher than last year (20.4%).
Past Earnings Growth Analysis
Earnings Trend: ALBIO has become profitable over the past 5 years, growing earnings by 121.3% per year.
Accelerating Growth: ALBIO's earnings growth over the past year (231.5%) exceeds its 5-year average (121.3% per year).
Earnings vs Industry: ALBIO earnings growth over the past year (231.5%) exceeded the Medical Equipment industry 22.5%.
Return on Equity
High ROE: ALBIO's Return on Equity (62%) is considered outstanding.
How is Biosynex's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ALBIO's short term assets (€198.8M) exceed its short term liabilities (€52.9M).
Long Term Liabilities: ALBIO's short term assets (€198.8M) exceed its long term liabilities (€48.2M).
Debt to Equity History and Analysis
Debt Level: ALBIO has more cash than its total debt.
Reducing Debt: ALBIO's debt to equity ratio has reduced from 34.6% to 20.4% over the past 5 years.
Debt Coverage: ALBIO's debt is well covered by operating cash flow (320.5%).
Interest Coverage: ALBIO's interest payments on its debt are well covered by EBIT (405.7x coverage).
What is Biosynex current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ALBIO's dividend (11.99%) is higher than the bottom 25% of dividend payers in the French market (1.72%).
High Dividend: ALBIO's dividend (11.99%) is in the top 25% of dividend payers in the French market (5.01%)
Stability and Growth of Payments
Stable Dividend: Too early to tell whether ALBIO's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if ALBIO's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (19.8%), ALBIO's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (22.7%), ALBIO's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...
Experienced Board: ALBIO's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biosynex SA's employee growth, exchange listings and data sources
- Name: Biosynex SA
- Ticker: ALBIO
- Exchange: ENXTPA
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €178.493m
- Shares outstanding: 10.32m
- Website: https://www.biosynex.com
Number of Employees
- Biosynex SA
- 22 Boulevard Sébastien Brant
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.